|
Barrett Esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients with gastroesophageal reflux disease (n = 181) who underwent upper-gastrointestinal endoscopy with biopsies of the distal esophagus to rule out BE using HE/AB staining and CDX-2 immunostaining were followed for 3 years.
|
31691172 |
2019 |
|
Barrett Esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
Biopsy samples from cases of human Barrett's metaplasia were analysed for the presence of CDX2 and HNF4α.
|
27875772 |
2017 |
|
Barrett Esophagus
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
On ectopic expression of CDX2, these transitional basal progenitors differentiate into intestinal-like epithelium (including goblet cells) and thereby reproduce Barrett's metaplasia.
|
29019984 |
2017 |
|
Barrett Esophagus
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CDH17 and CDX2 showed a significantly higher expression in BE, dysplasia, and EAC compared to CLE.
|
28807490 |
2017 |
|
Barrett Esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
CDX2 is a crucial factor in the development of pre-cancerous lesions such as Barrett's esophagus or intestinal metaplasia in the stomach, and its tumor suppressive role has been investigated in colorectal cancers.
|
27729732 |
2016 |
|
Barrett Esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, our study establishes a role for transcription factors SOX2 and CDX2 in the progression from gastric to gastrointestinal differentiation in Barrett's metaplasia.
|
27766003 |
2016 |
|
Barrett Esophagus
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Cdx2, an intestine specific transcription factor, is expressed in Barrett's esophagus (BE).
|
26460825 |
2015 |
|
Barrett Esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genomic DNA was extracted from blood samples collected from BE (n = 109) and GERD (n = 223) patients for genotyping of 5 SNPs each of Cdx1 and Cdx2 using TaqMan allelic discrimination assays.
|
23918153 |
2014 |
|
Barrett Esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
The following paper on the molecular biology of Barrett's esophagus (BE) includes commentaries on signaling pathways central to the development of BE including Hh, NF-κB, and IL-6/STAT3; surgical approaches for esophagectomy and classification of lesions by appropriate therapy; the debate over the merits of minimally invasive esophagectomy versus open surgery; outcomes for patients with pharyngolaryngoesophagectomy; the applications of neoadjuvant chemotherapy and chemoradiotherapy; animal models examining the surgical models of BE and esophageal adenocarcinoma; the roles of various morphogens and Cdx2 in BE; and the use of in vitro BE models for chemoprevention studies.
|
24117650 |
2013 |
|
Barrett Esophagus
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In addition to upregulation of CDX1 and CDX2, ASBT expression is up-regulated in BE.
|
23687410 |
2013 |
|
Barrett Esophagus
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
However, the relationship between the Notch signaling pathway and Cdx2 expression in the development of Barrett's esophagus has not been explored.
|
22449796 |
2012 |
|
Barrett Esophagus
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
While Cdx2 is ectopically induced in the early metaplastic condition of Barrett's esophagus, its expression is not necessarily present in progressive Barrett's with dysplasia or adenocarcinoma.
|
21935353 |
2011 |
|
Barrett Esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
The following on molecular mechanisms of Barrett's esophagus and adenocarcinoma contains commentaries on the mechanism of bile and gastric acid induced damage; the roles of BMP-4 and CDX-2 in the development of intestinal metaplasia; the transcription factors driving intestinalization in Barrett's esophagus; the contribution of bone marrow to metaplasia and adenocarcinoma; activation and inactivation of transcription factors; and a novel study design targeting molecular pathways in Barrett's esophagus.
|
21950830 |
2011 |
|
Barrett Esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present paper, we review the evidence for the role of Cdx2 in the development of Barrett's metaplasia.
|
20298184 |
2010 |
|
Barrett Esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
An important candidate gene for the causation of Barrett's metaplasia is Cdx2 (Caudal-type homeobox 2).
|
20298175 |
2010 |
|
Barrett Esophagus
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Ectopic expression of Cdx1 and Cdx2 occurs in both gastric IM as well as in BE.
|
21075347 |
2010 |
|
Barrett Esophagus
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Acid and bile salts induce CDX2 mRNA and protein expression in esophageal squamous cells from patients with Barrett's esophagus, but not from GERD patients without Barrett's esophagus.
|
20303354 |
2010 |
|
Barrett Esophagus
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These findings suggest that the inhibition of nucleostemin expression in "esophageal stem cells" in response to bile acid exposure may be involved in the pathogenesis of BE through upregulating CDX2 expression.
|
19449081 |
2009 |
|
Barrett Esophagus
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Pathogenesis of Barrett's esophagus: bile acids inhibit the Notch signaling pathway with induction of CDX2 gene expression in human esophageal cells.
|
19789031 |
2009 |
|
Barrett Esophagus
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A key event in the pathogenesis of BM is the induction of oesophageal CDX2 expression.
|
19564133 |
2009 |
|
Barrett Esophagus
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Relative to matched normal esophageal epithelia, CDX2 was overexpressed in esophagitis (37% for RNA; cytoplasmic immunoreactivity in 48% of tissues), a high proportion (91%) of BE tissues, and in EADC (57% for RNA; cell nuclear immunopositivity in 80%).
|
19415720 |
2009 |
|
Barrett Esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data suggested an important role of CDX1 and CDX2 in the development of BE.
|
19468668 |
2009 |
|
Barrett Esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
Evidence suggests that Barrett's esophagus intestinal metaplasia may occur via induction of caudal homeobox gene 2 (CDX2).
|
18854960 |
2009 |
|
Barrett Esophagus
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Caudal-related homeobox 2 (CDX2) is a transcription factor recently implicated in early differentiation and maintenance of normal intestinal epithelium and is suggested to play a key role in the pathogenesis of intestinal metaplasia in Barrett's esophagus.
|
17458588 |
2007 |
|
Barrett Esophagus
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The simultaneous up-regulation of both CDX2 and MUC2 after bile acid exposure provides molecular evidence of the role of bile acid in the pathogenesis of Barrett esophagus.
|
17576890 |
2007 |